Merck's New $140 Target Looks Easy-Unless Keytruda's Shield Falters Too Soon

Guggenheim's higher target raises the upside case, but not the core question

The headline is straightforward: Guggenheim lifted its Merck target to $140 from $122, and the stock is already near the top of its range at $119.75, just 2% below its 52-week high. If that optimism proves right, there is still some room.

But a higher target does not settle the harder question: whether Merck has bought itself enough time after Keytruda. Management's 2026 revenue guide of $65.5 billion to $67.0 billion came in below the $67.6 billion LSEG consensus, even after a fourth quarter where revenue beat estimates on strong Keytruda demand. The current engine is still doing most of the pulling, and the next growth bridge is still being tested.

That is why the debate remains alive. Bulls can point to Merck's long record of dividend resilience and its financial flexibility. Bears will point to the same guidance miss and ask whether enough other products can scale quickly if Keytruda's runway shortens.

Merck's latest quarter shows scale, but also continued dependence on Keytruda

The numbers show a large business still growing

One operating report is not a final verdict, but it does show where the business stands. In the fourth quarter, Merck generated $16.4 billion in sales, up 5% year over year. Full-year sales reached $65.0 billion, while Keytruda contributed $31.7 billion. That is a large, still-growing business.

At the same time, the dependency problem is easy to see. Keytruda accounted for more than half of pharmaceutical sales Keytruda accounted for more than 50% of pharmaceutical sales, which helps explain why investors are watching the handoff so closely.

Newer products are contributing, but the handoff is not fully proven

The positive read is that other assets are starting to matter more. Winrevair reached $1.4 billion in 2025 sales and then posted $588 million in the most recent quarter, up 75%. Capvaxive also reached $759 million in sales. Animal health remains a steadier contributor, with 8% growth in both the quarter and the full year. Even Keytruda was not static: quarterly Keytruda/Keytruda Qlex sales were $8.4 billion, up 5%, and included $463 million from Keytruda Qlex.

The cautious read is that the replacement engine still has to scale. The products look viable, and the launches are working, but one core asset still drives most of the revenue mix. That makes timing more important than branding. Strong launches are encouraging; they are not the same as a fully diversified growth engine.

What would validate or challenge the bullish case

With shares already just 2% below their 52-week high and Guggenheim still calling for upside after a guidance shortfall, the debate is less about whether Merck has good medicines and more about whether the replacement story can advance quickly enough.

Signals that would strengthen the case

• The next few quarters show newer products actually replacing sales lost to patent expiration and generic competition.
• Winrevair keeps building momentum, with upcoming Phase 2 CADENCE data in patients with Cpc-PH due at ACC 2026.
• Capvaxive continues to perform well outside Keytruda Capvaxive and Winrevair to drive its long-term growth.
• Animal health keeps adding a steadier growth thread.
• Keytruda keeps growing modestly while the broader portfolio picks up more of the load.

Signals that would weaken the case

• Another quiet quarter on substitution would make the stock look priced too early, especially after the guidance miss.
• If Keytruda's 2028 loss of exclusivity starts to matter before newer products are clearly big enough, the setup becomes less forgiving.
• Winrevair's momentum weakens if competition in the PAH space limits commercial progress.
• More pressure from patent expiration and generic competition would leave less room for error in the handoff.

For now, this still looks like a hold/watch setup. The bullish case works if substitution shows up quarter by quarter. The next few results should make clear whether Merck is earning that optimism or merely borrowing it.